

Fish Oil in Primary and Secondary Cardiovascular Prevention

Surya M. Artham, MD,* Carl J. Lavie, MD, Richard V. Milani, MD,* Rishi G. Anand, MD,*
James H. O'Keefe, MD,† Hector O. Ventura, MD*

*Department of Cardiology, Ochsner Clinical Foundation, New Orleans, LA

†Mid America Heart Institute and University of Missouri-Kansas City, Kansas City, MO

ABSTRACT

Omega-3 fatty acid therapy shows great promise in both primary and secondary prevention of cardiovascular (CV) diseases, especially coronary heart disease (CHD). In this review, we discuss the evidence available from prospective and retrospective observational epidemiologic studies and controlled clinical trials demonstrating the effects of omega-3 fatty acids (fish oil) in primary and especially secondary prevention of major CV events, including CV mortality, fatal and nonfatal myocardial infarction (MI), and sudden cardiac death (SCD). Significant reductions in total mortality and SCD to the extent of 20% to 50% have been found in studies using doses ranging from 0.85 to 4.0 g/d. We review the compelling evidence that indicates all clinicians should strongly consider therapy with fish oil, specifically eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), for patients with known CV disease and for patients at increased risk for CV disease, particularly patients at increased risk for SCD. The target DHA + EPA consumption levels are about 800 to 1000 mg/d for individuals with known CHD and at least 500 mg/d for individuals without disease.

INTRODUCTION

Substantial data indicate that elevated levels of low-density lipoprotein cholesterol (LDL-C), elevated levels of triglyceride-rich lipoproteins, and low levels of high-density lipoprotein cholesterol (HDL-C) are strongly associated with coronary heart disease

(CHD).^{1–3} Platelets also play an important role in the pathogenesis of atherosclerosis and its complications.^{4–6} Numerous other risk factors for atherosclerosis, including elevated blood pressure, should be kept under control in the prevention of CHD.⁷ Omega-3 fatty acids are increasingly being utilized to provide substantial protection against cardiovascular (CV) disease.^{8–12} Table 1¹¹ summarizes the major classes of fatty acids; α -linolenic acid (ALA) is the prototype of the omega-3 fatty acids, which include eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Numerous prospective and retrospective observational epidemiologic studies and randomized controlled trials from several countries, including Japan, India, and the United States, have shown that moderate fish oil consumption decreases the risk of major CV events, including myocardial infarction (MI) and sudden cardiac death (SCD).^{13–22} The purpose of the present review is to briefly summarize the effects of omega-3 fatty acids in primary and secondary prevention of CHD and SCD, including their effects on high-grade ventricular dysrhythmias and atrial fibrillation (AF). Finally, we conclude with a brief review of fish oil indications, their safety profile, and treatment guidelines.

FISH OIL AND PRIMARY PREVENTION

As early as 1944, Sinclair described the rarity of CHD in Greenland Eskimos despite their consumption of diet high in fat and cholesterol.²³ Sinclair observed that the Eskimos had a tendency to bruise and to bleed easily, and subsequently Bang and Dyerberg demonstrated that the Eskimos had reduced platelet counts (50 000–80 000/mm³ lower) and decreased platelet aggregation, resulting in prolonged bleeding times. Bang and Dyerberg^{24,25} and Dyerberg et al,²⁶ in their study comparing Greenland Eskimos and Danish controls, found, as expected, that the Eskimos, who eat about 500 g of fish per person per day (compared with 10–20 g/d in Westernized societies), had considerably higher levels of omega-3 fatty acids and lower levels of arachidonic acid in plasma, platelets, and red blood cell (RBC) membranes. Interestingly, in addition to reduced rates of CHD, the Greenland Eskimos also had a more favorable lipid profile and low levels of

Address correspondence to:

Carl J. Lavie, MD, FACC, FACP, FCCP
Medical Director, Cardiac Rehabilitation and Prevention
Director, Exercise Laboratories
Ochsner Clinical Foundation
1514 Jefferson Highway
New Orleans, LA 70121
Tel: (504) 842-5874
Fax: (504) 842-5875
Email: clavie@ochsner.org

Key Words: Coronary heart disease prevention, DHA, docosahexaenoic acid, eicosapentaenoic acid, EPA, fish oil, omega-3 fatty acids

Table 1. Major Classes of Fatty Acids*

Family†	Fatty Acids	Formula‡	Source
I Omega-9	Oleic acid	C16:1	Olive oil, vegetable oils, animal fats
II Omega-6	Linoleic acid	C18:2	Vegetable oils
	Arachidonic acid	C20:4	Poultry, meats
III Omega-3	α -Linolenic acid	C18:3	Marine and land plants§
	EPA	C20:5	Marine oils and fish
	DHA	C22:6	Marine oils and fish
IV Saturated fats	Palmitic acid	C16:0	Animal and vegetable fats
	Stearic acid	C18:0	Butter, lard, palm oil, palm kernel oil, coconut oil

* Adapted from Lavie and Milani.¹¹

† The omega number refers to the position of the first double bond from the methyl end of the molecule.

‡ The notation shows the total number of carbon atoms and total number of double bonds.

§ A particularly good source is rapeseed, commercially available as canola oil.

IEPA indicates eicosapentaenoic acid; DHA, docosahexaenoic acid.

blood pressure. Coronary heart disease is also less prevalent in Japan, despite higher prevalences of hypertension (HTN) and smoking, which may be partly due to the Japanese population's traditionally high consumption of fish compared to populations in the Western world. Even within Japan, the Japanese islanders, who eat 3 times more fish compared to the mainland population, have lower rates of HTN, CHD, and all-cause mortality.^{8,11}

In Westernized society, there is also evidence that increased consumption of fish is associated with decreased CHD. In the Zutphen study¹³ from the Netherlands, the 20-year mortality rate was 50% lower among those who ate 30 g of fish per day compared to those who did not eat fish. Data from the Multiple Risk Factor Intervention Trial (MR-FIT) in 6250 participants demonstrated reduction in 10-year mortality rates with increased consumption of polyunsaturated fatty acids.¹⁴ The US Physicians Health Study of 20 551 male physicians, of ages ranging from 40 to 84 years, demonstrated that consumption of fish at least once per week resulted in a 52% reduction in SCD during 11 years of follow-up.¹⁵ Patients in this study did not have any CV or cerebrovascular diseases prior to their enrollment in the study. The Nurses Health Study¹⁶ recently examined the dietary habits and the incidence of all kinds of strokes in 79 839 female nurses (ages 30 to 55 y at the time of enrollment). At the end of 14 years of follow-up, significant reductions in both thrombotic and lacunar strokes were noticed among women who consumed fish 2 or more times per week. This benefit was more apparent in women with higher baseline risk for stroke and those not taking aspirin. Similar positive effects of fish consumption on CV outcomes were noticed in the Honolulu Heart Program,²⁷ where heavy smokers with high fish consumption were at lower risk for CHD

mortality than those who smoked heavily and had low fish consumption. Table 2 outlines the potential beneficial effects of fish oils.⁸

On the contrary, there are a few epidemiologic studies that failed to show beneficial effects of high

Table 2. Potential Beneficial Effects of Fish Oils*

Platelets
Increased PGI ₃ † and decreased TXA ₂
Decreased platelet aggregation
Prolonged platelet survival
Decreased beta thromboglobulin, platelet factor 4, and probably platelet-derived growth factor
May decrease platelet adhesiveness
Lipids
Markedly decreased triglycerides
In healthy persons and in those with types IIb, IV, and V hyperlipoproteinemia
Prevented carbohydrate-induced TG rises
Lowered cholesterol
In healthy persons and in those with hypercholesterolemia
Prevented rise in cholesterol, even with diet extremely high in cholesterol
Lowered arterial pressure in normotensives and hypertensives
Decreased whole-blood viscosity and increased RBC deformability
Decreased coronary atherosclerosis in animals
Decreased atherosclerotic changes in vein bypass grafts
Decreased size and sequelae of cerebral infarction and MI in animals
Decreased restenosis by 50% following PTCA in human beings
Anti-inflammatory effects

* Reprinted with permission from Lavie et al.⁸

† PGI₃ indicates prostacyclin I₃; TXA₂, thromboxane A₂; TG, triglycerides; RBC, red blood cell; MI, myocardial infarction; and PTCA, percutaneous transluminal coronary angioplasty.

fish oil consumption on CV events. The Health Professionals Follow-up Study²⁸ found that increasing fish intake from 1 to 2 servings per week to 5 or 6 servings was not associated with any reduction in the risk of CHD among men who were initially free of CV disease. A case-control evaluation of 14 916 participants from the Physicians Health Study group²⁹ demonstrated similar baseline levels of EPA and DHA in those who had an MI versus those who did not have an MI during 5 years of follow-up. The Health Professionals Follow-up Study²⁸ and the Physicians Health Study²⁹ included cohorts with potentially higher baseline intake of omega-3 polyunsaturated fatty acids (PUFAs) than those in other cohort studies. These studies also involved cohorts at low risk of CHD and included few participants with low fish consumption (less than once per week). A threshold effect in which fish intake is cardioprotective in small amounts may partially explain these discordant results.^{30,31}

The Japan EPA lipid intervention study (JELIS),¹⁷ a primary and secondary prevention trial, tested the hypothesis that long-term addition of 1800 mg/d of highly purified EPA to statin (ie, simvastatin and pravastatin) therapy can reduce the incidence of major CV events in Japanese patients with hypercholesterolemia. JELIS randomized 14 981 patients for primary prevention and 3664 patients for secondary prevention in a prospective open-label, blinded endpoint study with a 4.6-year follow-up. In addition to the large sample size, this study had the advantages that all patients were given low-dose statin therapy and continued to consume a diet rich in omega-3 fatty acids. At the end of 54 months, the primary endpoint of the trial, major adverse CHD events (composite end point of nonfatal MI, CHD death, unstable angina, and revascularization procedures) was reduced by 19% ($P = .015$). There was no significant reduction in SCD among patients receiving therapy for primary prevention or even among patients treated for secondary prevention. This finding seems to be at odds with the GISSI-Prevenzione trial,¹⁸ which reported a 45% decrease in the risk of SCD in post-MI patients. The authors of the JELIS trial reconcile this difference by stating that Japanese populations already consume more fish compared to Western populations and that their baseline population CV death rates are lower than those in the Western world. Therefore, there might be a dose beyond which additional antiarrhythmic effects may not be seen.³⁰ However, these findings suggest that the benefits of omega-3 fatty acids may also be found in populations consuming large amounts of fish, ie, with higher doses of omega-3 fatty acids, cardioprotective effects other than arrhythmia reduction may be observed. Reductions in the incidence of unstable

angina and nonfatal CHD events suggest that other, plaque-stabilizing properties may also be involved with omega-3 fatty acid therapy.^{30,32}

FISH OIL AND SECONDARY CV PREVENTION

There is now mounting evidence suggesting that fish oil has substantial beneficial effects in the secondary prevention of CV events. In the GISSI-Prevenzione trial,¹⁸ 11 323 patients who had suffered an MI within the previous 3 months were randomized to receive a fish oil supplement (1 g daily containing 850 mg of concentrated EPA and DHA) versus no supplement, 300 mg of a vitamin E supplement versus no supplement, and both supplements versus no supplements. The primary combined efficacy endpoint was death, nonfatal MI, and stroke. Patients taking fish oil supplements had a 15% risk reduction in the primary endpoint, including 21% and 30% reductions in total and CV mortality, respectively. Further analysis revealed that this endpoint reduction was driven by a highly significant 44% reduction in SCD^{18,33,34} (Figure 1). Moreover, SCD reduction reached statistical significance after only 4 months of randomization. However, vitamin E showed no efficacy alone or in combination with fish oil.^{33,34} The authors concluded that in order to save 1 patient in a population at relatively low risk (annual mortality 2.6%), 164 patients would need to be treated for 1 year with omega-3 fatty acids.³³

Thus, the antiarrhythmic effect observed in the GISSI trial is due to the low background dietary intake of omega-3 fatty acids, high baseline risk of SCD, and entry requirement of a recent MI. In contrast, the other existing literature, including the JELIS trial, suggests that the reduction of nonfatal CHD events may require higher doses (2–3 g/d of DHA + EPA) and/or a longer duration of treatment (3 to 5 y).^{17,30} In a subgroup analysis of findings from the GISSI trial, Macchia and colleagues³⁵ found that the magnitude of reduction in mortality due to SCD increased with progressively worsening left ventricular (LV) systolic function (Figure 2). The effect of n-3 PUFA treatment on SCD was related to the degree of systolic dysfunction (test for trend $P = 0.02$), with the benefit on SCD reduction in patients with ejection fraction (EF) less than or equal to 40% being 4-fold higher than in those with EF greater than 50%.

The Diet and Reinfarction Trial (DART)¹⁹ examined the effects of dietary intervention in the secondary prevention of MI in 2033 men who recovered from a recent MI, and these patients were allocated to 3 different dietary advice groups: (1) fat advice group, in which participants were advised to reduce dietary fat intake to 30% of total energy and to increase the polyunsaturated/saturated (P/S) ratio to 1; (2) fiber advice group, in which participants were advised to




Figure 1. Early benefit of omega-3 fatty acid therapy on total mortality, sudden death, coronary heart disease mortality, and cardiovascular mortality. Probability measurements represent relative risk (95% confidence interval). (Reproduced with permission from Marchioli R, Barzi F, Bomba E, et al. *Circulation* 2002;105:1897–1903.³³)

increase their intake of cereal fiber to 18 g daily; and (3) fish advice group, in which participants were instructed to either eat at least 2 weekly portions (200–400 g) of fatty fish (mackerel, herring, kipper, pilchard, sardine, salmon, or trout) or to take a daily fish oil supplement. After 2 years of follow-up, the fish/fish oil group showed a 29% reduction in all-cause mortality compared to the remaining 2 groups ($P < 0.05$), with the difference entirely attributable to a reduction in CHD deaths. The reduction in CV events was particularly impressive in the subgroup that took the fish oil supplement as opposed to simply increasing dietary fish consumption.

The Indian Study on Infarct Survival²⁰ also demonstrated a significant effect of omega-3 fatty acid therapy on mortality in patients who had an MI. In this study, 360 Indian patients were randomized within 24 hours following an MI to receive fish oil providing 1.08 g/d of EPA plus 0.72 g/d of DHA; 20 g/d of mustard seed oil (the fatty acid composition of which is predominantly oleic acid, linoleic acid, and erucic acid); or a placebo of 100 mg/d of aluminum hydroxide. The combined primary endpoint of total CV events consisted of SCD, total CHD deaths, and nonfatal reinfarction. At 1-year follow-up, there were significant reductions in total CHD events and nonfatal MI and a




Figure 2. Effect of omega-3 fatty acids on sudden cardiac death in patients with progressive impairment of left ventricular systolic function. Squares are proportional to the number of cases. CI indicates confidence interval; EF, ejection fraction; HR, hazard ratio; and n-3 PUFA, omega-3 polyunsaturated fatty acids. (Reproduced with permission from Macchia A, Levantesi G, Franzosi MG, et al. *Eur J Heart Fail* 2005;7:904–909.³⁵)

50% reduction in SCD in the fish oil and mustard oil groups when compared with the placebo group. The fish oil and mustard oil groups also showed significant reductions in total cardiac arrhythmias, LV enlargement, and angina pectoris compared with the placebo group. The study population was significantly different from those in other published studies in that they were enrolled within 24 hours of symptoms of MI and were predominantly vegetarian, consistent with the demographics of the part of India where the trial was conducted, although no baseline data were provided for documentation. In addition, they did not receive the aggressive treatment typical of modern post-MI therapies. In fact, only 30% of patients were treated with beta-blockers and 20% with angiotensin-converting enzyme inhibitors, and the use of lipid-lowering drugs was not reported.

Increased intake of fish oil in several studies demonstrated an effect in retarding or even reversing the progression of atherosclerotic heart disease. Von Schacky and associates,³⁶ in the randomized, double-blind Study on Prevention of Coronary Atherosclerosis by Intervention with Marine Omega-3 fatty acids (SCIMO), evaluated the effects of omega-3 fatty acid therapy on angiographic endpoints in 223 patients using 6 g/d of fish oil (EPA + DHA, 3.3 g/d) for 3 months and then 3 g/d for 21 months versus placebo. Patients in the placebo group were treated with capsules containing a blend of oils comparable to that of the typical European diet, but the blend was free of EPA and DHA as well as the precursor omega-3 fatty acid ALA. All participants had a greater than 20% stenosis in at least 1 coronary artery on angiography and had revascularization (percutaneous coronary angiography or carotid artery bypass graft) planned or performed in the previous 6 months in no more than 1 vessel. Comparison of baseline versus posttreatment angiograms showed that coronary segments in the fish oil group showed less progression and more regression than segments in the placebo group. A very small study by Sacks and colleagues³⁷ in 59 patients was designed to examine differences in angiographic endpoints, and the authors also reported CV events. Thirty-one patients on fish oil (6 g/d) were compared with 28 patients receiving an olive oil placebo. Fish oil therapy did not result in significant reductions either in the incidence of CV death and MI or in revascularization rates in this very underpowered study.

FISH OIL AND HIGH-RISK VENTRICULAR ARRHYTHMIAS

Recently reviewed cumulative data by Anand et al³² demonstrate benefits of DHA + EPA against AF as well as trends toward benefits in malignant ventricular arrhythmias. Although omega-3 fatty acids appear to

be effective for reducing SCD in the setting of CHD with reduced LV systolic function, 3 trials using omega-3 fatty acids in patients with implantable cardioverter defibrillators (ICDs) have shown mixed results. Raitt et al³⁸ examined whether omega-3 PUFAs have any beneficial antiarrhythmic effects in patients with electrocardiographically documented ventricular tachycardia and fibrillation (VT/VF). The study randomized 200 patients with ICDs to treatment for 2 years with either 1.8 g/d of an omega-3 fatty acid supplement containing 42% EPA and 30% DHA ethyl esters or an olive oil placebo. The primary endpoint was time to first episode of ICD treatment for VT or VF. Although the treatment groups did not differ significantly in the number of episodes of VT and VF observed during follow-up, an overall trend toward an increased incidence of VT and VF was observed in the group receiving omega-3 fatty acid supplementation. In the subset of 133 patients whose entry arrhythmia was VT, 79% of the patients in the fish oil group experienced VT/VF at 24 months compared to 65% of patients in the control group ($P = .007$). The omega-3 fatty acid group had significantly higher rates of recurrent episodes of VT or VF compared to the placebo group ($P < .001$), suggesting that these supplements may even be proarrhythmic in certain patients.

Another recently completed trial called the Fatty Acid Antiarrhythmia Trial (FAAT),³⁹ conducted by Leaf et al in 402 patients with an ICD, randomized patients to 2.6 g/d of omega-3 fatty acids versus 4 g/d of an olive oil placebo. The primary endpoint was time to first ICD event for VT or VF or death from any cause. The noncompliance rate was high but similar between the 2 groups. Despite this shortcoming, at 1 year follow-up, the omega-3 fatty acid group showed a positive trend toward a longer time to first ICD event (VT or VF) or death from any cause, with a risk reduction of 28% ($P = .057$). However, when the authors included probable episodes of VT/VF, the risk reduction became statistically significant at 31% ($P = .033$). Moreover, after adjusting for subjects who were compliant for 11 months or longer, the risk reduction approached 38% ($P = .034$). In subgroup analysis, the effect was greatest in patients with CHD and in those with left ventricular ejection fraction less than 30%.

The antiarrhythmic effects of omega-3 fatty acids have also been investigated in another recently completed multicenter, randomized, double-blind parallel trial, the Study on Omega-3 Fatty Acids and Ventricular Arrhythmia (SOFA).⁴⁰ The trial included 546 patients with an ICD in place who had at least 1 episode of VT or VF during the previous year. Patients were randomized to 2 g of fish oil (464 mg EPA and 335 mg DHA) or high-oleic acid sunflower oil placebo for 12 months. The primary outcome was incidence

of recurrent spontaneous VT or VF and all-cause mortality. At 1 year, no observable event-free survival difference was observed between treatment groups (70% vs 67% for fish oil vs placebo). However, in subgroup analysis, in patients with prior MI ($n = 342$), there was a nonsignificant trend toward longer event-free survival in the fish oil group compared with the placebo group (71% vs 63%, $P = .09$).

The authors speculate that the positive effects observed in FAAT,³⁹ in contrast to the negative results reported in SOFA⁴⁰ and in the trial by Raitt and associates,³⁸ may be attributed to the possible inclusion of 2 very different ICD populations. FAAT included patients with recent MI, whereas Raitt et al did not have any patients with recent MI, suggesting that fish oil therapy may be more beneficial in preventing ventricular arrhythmia in CHD patients, especially those with recent MI, as there is a lower amount of scar tissue in these patients.

Overall, 2 of the 3 ICD trials support at least a modest benefit of omega-3 PUFAs for the prevention of high-risk ventricular arrhythmias.^{32,41} Omega-3 PUFAs also appear to be effective in reducing SCD in patients with ischemic LV systolic dysfunction.³⁵ Results of the ongoing large randomized GISSI-Heart Failure Study (GISSI-HF or GISSI V) involving 7000 heart failure (HF) patients are anticipated in 2008 and should shed more light on the effects of DHA + EPA on outcomes in patients with reduced LV systolic function.⁴²

FISH OIL AND AF

Recent research has suggested a greater role for omega-3 fatty acids not only with respect to ventricular arrhythmias and autonomic tone but also in the management of AF. Mozaffarian et al⁴³ demonstrated a 30% lower risk of incident AF over a 12-year follow-up period in patients who consumed tuna or other broiled/baked fish. The relationship between increased fish consumption and lower incidence of AF persisted even after correcting for variables such as age, gender, education, smoking, CHD history, diabetes, HF, and MI. However this does not prove causality. Another study, from Calò and colleagues,⁴⁴ investigated the effect of preoperative and postoperative treatment with omega-3 PUFAs in preventing the occurrence of AF after bypass surgery in a total of 160 patients with no prior history of AF. Patients were randomized to an omega-3 PUFA group, who received an average dose of 850 to 882 mg/d of EPA and DHA from a variety of commercially available preparations, vs a placebo control group. Omega-3 supplementation was initiated 5 days prior to surgery and was continued until the seventh postoperative day on average. New-onset postoperative AF was noticed in 33.3% of the control cohort and in 15.2% of the PUFA cohort ($P = .013$).

After bypass, the PUFA patients were also hospitalized for significantly fewer days than controls (7.3 ± 2.1 vs 8.2 ± 2.6 d, $P = .017$). Crystal et al⁴⁵ described efficacy of omega-3 PUFAs comparable to amiodarone, beta-blockers, and sotalol in prophylaxis against AF postbypass. In view of this evidence, omega-3 PUFAs could be used to prevent AF postbypass particularly in patients with contraindications to sotalol or beta-blockers (ie, chronic obstructive lung disease or bradycardia), and it is thought that the antiarrhythmic and anti-inflammatory properties of PUFAs could have played an essential role in preventing AF after cardiothoracic surgery.³²

OMEGA-3 MECHANISMS

Omega-3 fatty acids appear to confer CV health benefits largely through DHA and EPA enrichment of membrane phospholipids.⁴⁶⁻⁴⁸ Large doses (3-5 g/d) of fish oil have been shown to produce a 30% to 50% reduction in triglycerides, whereas in most studies low-dose therapy (eg, 1 g/d) has not been associated with any lipid improvements, although the GISSI trial using 850 mg/d did show a very small (3.4%) but statistically significant reduction in triglycerides.¹⁸ Therefore, other mechanisms must play a major role in the clinical effects of fish oil, particularly in the antiarrhythmic effects and in the reduction of SCD.^{30,32} Table 3 shows the relationship between baseline blood levels of long-chain omega-3 fatty acids and risk of SCD. The level of long-chain n-3 fatty acids was significantly and inversely related to the risk of SCD.⁴⁹

A relatively low daily dose of 810 mg of DHA + EPA has been shown to decrease resting heart rate, increase postexercise heart rate recovery, and increase beat-to-beat heart rate variability, all of which represent improved autonomic tone, or the balance between vagal/sympathetic activity.^{50,51} Moreover, high doses of fish oil have also been shown to lower blood pressure.^{52,53} More than a decade ago, we demonstrated that fish oil therapy resulted in a significant 25% reduction in mean arterial pressure and systemic vascular resistance, a modest reduction in LVH, and modest improvements in LV diastolic filling in cardiac transplant patients with cyclosporine-induced hypertension.⁵² These changes appear to be manifestations of augmented vagal tone, suggesting that omega-3 fatty acids may confer cardioprotection in part by improving autonomic sympathovagal balance.⁵⁴ Fish oils, similar to long-term exercise, have many properties in the blood leading not only to increased fibrinolytic activity but also to reduced whole-blood viscosity and increased red blood cell deformability, all of which improve tissue perfusion at a cellular level.⁵⁵ Other studies in heart transplant patients, however, suggest that the omega-3 fatty acid-

Table 3. The Relation of Baseline Blood Levels of Long-Chain n-3 Fatty Acids to the Risk of Sudden Death*†

Variable	Quartile of n-3 Polyunsaturated Fatty Acid				P Value for Trend
	1	2	3	4	
Fatty acid level (%):‡					
Mean	3.58	4.76	5.63	6.87	
Range	2.12–4.32	4.33–5.19	5.20–6.07	6.08–10.2	
Model adjusted for age and smoking status					
Relative risk	1	0.47	0.37	0.31	0.004
95% confidence interval		0.22–1.00	0.17–0.83	0.13–0.75	
Multivariate model 1§					
Relative risk	1	0.55	0.28	0.19	0.007
95% confidence interval		0.18–1.70	0.09–0.87	0.05–0.71	
Multivariate model 2					
Relative risk	1	0.52	0.19	0.1	0.001
95% confidence interval		0.16–1.72	0.05–0.69	0.02–0.48	

* Reprinted with permission from Albert et al.⁴⁹

† Long-chain n-3 polyunsaturated fatty acids found in fish include docosahexaenoic acid, eicosapentaenoic acid, and docosapentaenoic acid. The level of long-chain n-3 fatty acids was significantly inversely related to the risk of sudden death in both the analysis adjusted for age and smoking status (P for trend = .004) and the multivariate analysis (P for trend = .007).

‡ Levels are expressed as a percentage of total fatty acids.

§ Multivariate model 1 controlled for assignment to aspirin and beta carotene treatment or placebo, body mass index (subjects were classified as having values of less than 25, 25 to 30, or more than 30), history of diabetes, history of hypertension, history of hypercholesterolemia, alcohol consumption (monthly or less, 1 to 6 drinks per week, or daily), frequency of vigorous exercise (less than weekly or at least once weekly), and parental history of myocardial infarction before the age of 60 years.

||Multivariate model 2 included the variables in multivariate model 1 and the quartiles of *trans* unsaturated fatty acid and monounsaturated fatty acid levels.

induced improvements in autonomic tone may not be entirely vagally mediated.⁵⁶ Additionally, we recently demonstrated that very high doses of omega-3 fatty acids (ie, 8 g/d) provide anti-inflammatory effects and improve body composition in HF patients.⁵⁷

By reducing transcription of inflammatory cytokines and by other mechanisms, fish oil has been shown to have significant anti-inflammatory effects.⁵⁸ These effects may extend its use to patients with chronic inflammatory conditions such as rheumatoid arthritis and ulcerative colitis.^{59,60} These anti-inflam-

matory properties may also play an important role in stabilization of unstable plaque in patients with acute coronary syndrome (ACS).^{30–32} Eicosapentaenoic acid competes with arachidonic acid for the cyclooxygenase, leading to decreased synthesis of thromboxane A₂, which is a strong platelet agonist, and increases the synthesis of thromboxane A₃, which is relatively inactive, so the net effect of high doses of omega-3 fatty acids is platelet inhibition.^{11,30–32} Table 4 summarizes the clinical uses and recommendations of omega-3 fatty acids.

Table 4. Clinical Uses and Recommendations*

Clinical Use	Dosage	Comments
Primary prevention of cardiovascular disease	500 mg/d	Encourage at least 2 oily fish meals per week.
Secondary prevention of cardiovascular disease	1–2 g/d	May encourage dietary intake or fish oil supplementation
Hypertriglyceridemia	Initial 2–4 g; up to 12 g	For doses greater than 3 g, consider monitoring for bleeding side effects, LDL, and glycemic response
Infants (not breastfeeding)	0.35% of dietary fat as DHA	Consider omega-3 and omega-6 enriched infant formula
Women (pregnant and of childbearing age)	2 fatty fish meals a week (up to 12 oz)	Avoid shark, tilefish, king mackerel, swordfish. Limit albacore tuna to 6 oz per week.

* LDL indicates low-density lipoprotein; DHA, docosahexaenoic acid.

SIDE EFFECTS OF OMEGA-3 FATTY ACIDS

The most commonly observed side effects of omega-3 fatty acid supplementation are nausea, gastrointestinal upset, and a “fishy burp.” The US Food and Drug Administration (FDA) performed a comprehensive review of the safety of fish oil in 1997 and concluded that “consumers not exceed a total of 3 grams per day of EPA and DHA omega-3 fatty acids,” the equivalent of 10 1-g capsules of saturated fish oil (which is 30% DHA + EPA).^{30–32} Although prolonged bleeding times (present invariably within the normal range) have been noted with very high doses of omega-3 PUFAs (20 g/d), raising a concern for hemorrhagic complications, a recent update by Harris concluded that virtually no increased risk for clinically significant bleeding has been seen in patients with doses of omega-3 fatty acids up to 7 g/d of DHA + EPA, even when combined with aspirin or coumadin.^{61,62}

Omega-3 fatty acid supplementation may increase the level of LDL-C (usually <5%), but this is counterbalanced by its triglyceride-lowering property to the extent of 30% to 50%.^{2,8–11,63} Another potential danger from high fish intake is the consumption of toxic contaminants, such as methyl mercury. The FDA has recommended that children and pregnant or nursing women avoid mackerel, shark, swordfish, and tilefish, as they are known to often have high mercury levels.⁶⁴ Fortunately, as mercury is water soluble and protein-bound, it is predominantly localized to muscle tissues and therefore not found in fish oil extractions.⁶⁵ Fortunately, only negligible amounts of mercury are found in routinely consumed omega-3-rich fish and seafood including shrimp, trout, sardines, salmon, oysters, and herring.⁶⁶

TREATMENT GUIDELINES

We firmly believe that the current evidence strongly supports treatment with omega-3 fatty acids for secondary prevention in patients with CHD and as primary prevention in those with known risk factors for SCD, such as LV dysfunction, LV hypertrophy (LVH), prior MI, or high-grade ventricular arrhythmias. Although there are numerous over-the-counter fish oil supplements with varying amounts of DHA and EPA available on the market, a concentrated prescription omega-3 supplement similar to that used in the GISSI-Prevenzione study has been made available since 2005 (Lovaza, Reliant Pharmaceuticals, Liberty Corner, NJ). At present in the United States, prescription omega-3 fatty acids are approved by the FDA only for the treatment of very high triglyceride levels, and the recommended dose is 3.4 g of DHA + EPA per day, which can reduce triglyceride levels by 30% to 50%.^{67,68} Lovaza has been shown to reduce

Table 5. American Heart Association (AHA) Recommendations for Fish Oil*

Patient Population	Recommendations
Patients <i>without</i> documented coronary heart disease	Eat a variety of (preferably fatty) fish at least twice a week. Include oils and foods rich in α -linolenic acid (flaxseed, canola, and soybean oils; flaxseed and walnuts).
Patients <i>with</i> documented coronary heart disease	Consume approximately 1 g of EPA + DHA per day, preferably from fatty fish. EPA + DHA supplements could be considered in consultation with the physician.
Patients who need to lower triglycerides	2–4 g of EPA + DHA per day provided as capsules under a physician's care.

* <http://www.americanheart.org>.

severely elevated (>500 mg/dL) triglycerides by 45% and is the only agent to carry this indication at a dose of 4 capsules per day.^{68,69}

The current American Heart Association (AHA) dietary guidelines (Table 5) recommend combined use of EPA and DHA in a dose of approximately 1000 mg per day in patients with CHD.^{70,71} This dose is derived based on the results from GISSI-Prevenzione study,¹⁸ in which a dose of 850 mg was used. For those individuals with no known CHD or hypertriglyceridemia, the AHA recommends the consumption of about 2 oily fish meals per week, which is equivalent to nearly 500 mg of EPA + DHA per day.^{30,32} Table 6 describes the EPA + DHA content of different kinds of commonly consumed seafood. The most highly consumed fish and shellfish include tuna (representing 22% of total consumption), shrimp

Table 6. Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA) Content* of the Most Commonly Consumed Fish and Shellfish†

Fish	EPA	DHA	EPA + DHA
Tuna, canned	0.198	0.535	0.733
Shrimp	0.145	0.122	0.267
Cod	0.003	0.131	0.134
Salmon	0.587	1.238	1.825
Clams	0.117	0.124	0.241
Flounder	0.207	0.219	0.426
Catfish	0.042	0.109	0.151
Flatfish	0.207	0.291	0.498
Pollock	0.077	0.383	0.46
Haddock	0.065	0.138	0.203

* Grams of fatty acid per 3 oz of fish, cooked.

† Adapted from US Department of Agriculture.⁷²

Table 7. Best Fish Sources of Eicosapentaenoic acid (EPA) and Docosahexaenoic Acid (DHA)*†

Fish	EPA	DHA	EPA + DHA
Salmon, Atlantic, farmed	0.587	1.238	1.825
Herring, Pacific	1.056	0.751	1.807
Mackerel, Pacific	0.555	1.016	1.571
Sablefish	0.737	0.782	1.519
Whitefish	0.345	1.025	1.37
Halibut, Greenland	0.573	0.428	1.001
Trout, farmed	0.284	0.697	0.981
Bluefish	0.275	0.565	0.84
Tuna, white, canned	0.198	0.535	0.733
Shark	0.219	0.366	0.585

* All values in grams of fatty acid per 3 oz of fish, cooked.

† Adapted from US Department of Agriculture.⁷²

(16%), salmon (9%), mixed fish (8%), and crab (7%). Table 7 lists species of fish that are rich in EPA and DHA.⁷² We have combined data from multiple studies in order to get an assessment of the amount of EPA (or the dose of fish, fish oil, capsules, or cod liver oil) required to inhibit platelets or have positive effects on the blood lipid profile (Table 8).^{8,11,73}

The following are recommendations from major organizations on fish consumption:

- The AHA: consume fish, especially oily fish, at least twice a week.^{70,71}

- National Cholesterol Education Program (NCEP)—recommends fish as a food item for people to choose more often.⁷⁴
- World Health Organization (WHO)—regular fish consumption, 1 to 2 servings per week; each serving should provide the equivalent of 200 to 500 mg of EPA and DHA.⁷⁵
- European Society of Cardiology—oily fish and omega-3 fatty acids have particular protective properties for primary CV disease prevention.^{76–78}
- United Kingdom Scientific Advisory Committee on Nutrition—consume 2 or more portions of fish per week, of which 1 should be oily and provide 450 mg/day of EPA and DHA.⁷⁹
- American Diabetes Association—2 to 3 servings of fish per week provide adequate dietary omega-3 PUFAs.⁸⁰

CONCLUSIONS

Convincingly strong evidence from extensive research over the last 3 decades on the beneficial effects of fish oil therapy mandates that clinicians consider fish oil supplements for primary and secondary CV disease prevention, particularly in patients with high risk for SCD. To reinforce, current recommendations suggest that patients with known CHD should consume about 800–1000 mg/d of combined EPA/DHA, and individuals with no known disease should consume at least 500 mg/d. These doses of EPA/DHA can be obtained by consuming fatty fish or

Table 8. Cholesterol and Calories in Fish and Dietary Supplements Supplying 1 g Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA)*†

Fish or Supplement	Fat, g‡	EPA + DHA, g‡	Cholesterol, mg‡	Calories‡	Amount to Supply About 1 g		
					EPA + DHA, g	Cholesterol, mg	
Salmon (steamed)	6.6	1.0	74	199	100	74	199
Trout	3.4	0.5	57	131	200	114	262
Crab (broiled)	1.3	0.4	78	127	250	195	317
Cod							
(steamed)	0.7	0.2	37	82	500	185	410
(fried)	204	1020
Flounder							
(steamed)	1.0	0.2	46	53	500	230	265
(fried)	214	1070
Shrimp (broiled)	1.3	0.2	128	114	500	640	570
Lobster (broiled)	0.9	0.2	95	119	500	475	595
Cod-liver oil	100	22	500	930	5 (about 4 mL)	25	46
Max EPA	100	30	450	930	3 (3–4 capsules)	14	30

* Adapted from Lavie CJ et al.⁸

† Fish oil capsules containing up to 50% omega-3 fatty acids and having small amounts of cholesterol, vitamin A, and vitamin D are now also marketed.

‡ Values are per 100 g portion (Data from Reed⁷³).

by taking fish oil supplements. Patients with high triglyceride levels will benefit from large doses (3–4 g/d) of EPA/DHA, a dose that almost certainly would require fish oil supplements.

REFERENCES

- Lavie CJ, Gau GT, Squires RW, Kottke BA. Management of lipids in primary and secondary prevention of cardiovascular diseases. *Mayo Clin Proc.* 1988;63:605–621.
- Lavie CJ, O’Keefe JH, Blonde L, Gau GT. High-density lipoprotein cholesterol. Recommendations for routine testing and treatment. *Postgrad Med.* 1990;87:36–44, 47, 51.
- Lavie CJ. Lipid and lipoprotein fractions and coronary artery disease. *Mayo Clin Proc.* 1993 Jun;68:618–619.
- Lavie CJ, Genton E. Hemostasis, thrombosis, and antiplatelet therapy — implications for the prevention of cardiovascular diseases. *Cardiovasc Rev Rep.* 1991;12:24–47.
- Lavie CJ, Schmieder R, Genton E. Antiplatelet therapy for cardiovascular diseases. *Cardiovasc Rev Rep.* 1987;8:64–69.
- Lavie CJ, Schmieder R, Genton E. Hemostasis, thrombosis, and antiplatelet agents. *Cardiovasc Rev Rep.* 1987;8:25–29.
- Lavie CJ, Messerli FH. Hypertension and target organ disease. In: Messerli FH, ed. *The ABC’s of Antihypertensive Therapy.* New York: Raven Press, 1994:175–185.
- Lavie CJ, Squires RW, Gau GT. Preventive cardiology: what is the role of fish and fish oils in primary and secondary prevention. *J Cardiopulm Rehabil.* 1987;7:526–533.
- Lavie CJ, Squires RW, Gau GT. Preventive cardiology: what is the value of antiplatelet agents and fish oils? *South Med J.* 1988;81: 1145–1150.
- Lavie CJ, Milani RV. National Cholesterol Education Program’s recommendations, and implications of “missing” high-density lipoprotein cholesterol in cardiac rehabilitation programs. *Am J Cardiol.* 1991;68:1087–1088.
- Lavie CJ, Milani RV. Fish oils. In: Messerli FH, ed. *Cardiovascular Drug Therapy.* Philadelphia: W.B. Saunders Company, 1996: 1608–1613.
- Lavie CJ, Squires RW, Gau GT. Prevention of cardiovascular disease. Of what value are risk factor modification, exercise, fish consumption, and aspirin therapy? *Postgrad Med.* 1987;81: 52–54, 59–72.
- Kromhout D, Bosschieter EB, de Lezenne Coulander C. The inverse relation between fish consumption and 20-year mortality from coronary heart disease. *N Engl J Med.* 1985;312:1205–1209.
- Dolecek TA. Epidemiological evidence of relationships between dietary polyunsaturated fatty acids and mortality in the multiple risk factor intervention trial. *Proc Soc Exp Biol Med.* 1992;200:177–182.
- Albert CM, Hennekens CH, O’Donnell CJ, et al. Fish consumption and risk of sudden cardiac death. *JAMA.* 1998;279:23–28.
- Iso H, Rexrode KM, Stampfer MJ, et al. Intake of fish and omega-3 fatty acids and risk of stroke in women. *JAMA.* 2001;285:304–312.
- Yokoyama M, Origasa H, Matsuzaki M, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis [published correction appears in *Lancet.* 2007;370:220]. *Lancet.* 2007;369:1090–1098.
- Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial, Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto miocardico [Published corrections appear in *Lancet.* 2001;357: 642 and *Lancet.* 2007;369:106]. *Lancet.* 1999;354:447–455.
- Burr ML, Fehily AM, Gilbert JF, et al. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). *Lancet.* 1989;2:757–761.
- Singh RB, Niaz MA, Sharma JP, Kumar R, Rastogi V, Moshiri M. Randomized, double-blind, placebo-controlled trial of fish oil and mustard oil in patients with suspected acute myocardial infarction: the Indian experiment of infarct survival — 4. *Cardiovasc Drugs Ther.* 1997;11:485–491.
- O’Keefe JH Jr, Harris WS. From Inuit to implementation: omega-3 fatty acids come of age. *Mayo Clin Proc.* 2000;75:607–614.
- O’Keefe JH, Harris WS. Omega-3 fatty acids: time for clinical implementation? *Am J Cardiol.* 2000;85:1239–1241.
- Sinclair HM. The diet of Canadian Indians and Eskimos. *Proc Nutr Soc.* 1953;12:69–82.
- Bang HO, Dyerberg J. Plasma lipids and lipoproteins in Greenlandic west coast Eskimos. *Acta Med Scand.* 1972;192:85–94.
- Bang HO, Dyerberg J. Lipid metabolism and ischemic heart disease in Greenland Eskimos. *Adv Nutr Res.* 1980;3:1–22.
- Dyerberg J, Bang HO, Hjerne N. Fatty acid composition of the plasma lipids in Greenland Eskimos. *Am J Clin Nutr.* 1975;28: 958–966.
- Rodriguez BL, Sharp DS, Abbott RD, et al. Fish intake may limit the increase in risk of coronary heart disease morbidity and mortality among heavy smokers. The Honolulu Heart Program. *Circulation.* 1996;94:952–956.
- Ascherio A, Rimm EB, Stampfer MJ, Giovannucci EL, Willett WC. Dietary intake of marine n-3 fatty acids, fish intake, and the risk of coronary disease among men. *N Engl J Med.* 1995;332:977–982.
- Guallar E, Hennekens CH, Sacks FM, Willett WC, Stampfer MJ. A prospective study of plasma fish oil levels and incidence of myocardial infarction in US male physicians. *J Am Coll Cardiol.* 1995;25:387–394.
- Lee JH, O’Keefe JH, Lavie CJ, Marchioli R, Harris WS. Omega-3 for cardioprotection. *Mayo Clin Proc.* 2008;83:324–332.
- Alaswad K, Lavie CJ, Milani RV, O’Keefe JH Jr. Fish oil in cardiovascular protection. *Ochsner J.* 2002;4:83–91.
- Anand RG, Alkadri M, Lavie CJ, Milani RV. The role of fish oil in arrhythmia prevention. *J Cardiopulm Rehabil Prev.* 2008;28(2):92–98.
- Marchioli R, Barzi F, Bomba E, et al. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico (GISSI)-Prevenzione. *Circulation.* 2002;105:1897–1903.
- Leaf A. On the reanalysis of the GISSI-Prevenzione. *Circulation.* 2002;105:1874–1875.
- Macchia A, Levantisi G, Franzosi MG, et al. Left ventricular systolic dysfunction, total mortality, and sudden death in patients with myocardial infarction treated with n-3 polyunsaturated fatty acids. *Eur J Heart Fail.* 2005;7:904–909.
- von Schacky C, Angerer P, Kothny W, Theisen K, Mudra H. The effect of dietary omega-3 fatty acids on coronary atherosclerosis. A randomized, double-blind, placebo-controlled trial. *Ann Intern Med.* 1999;130:554–562.
- Sacks FM, Stone PH, Gibson CM, Silverman DI, Rosner B, Pasternak RC. Controlled trial of fish oil for regression of human

- coronary atherosclerosis. HARP Research Group. *J Am Coll Cardiol*. 1995;25:1492–1498.
38. Raitt MH, Connor WE, Morris C, et al. Fish oil supplementation and risk of ventricular tachycardia and ventricular fibrillation in patients with implantable defibrillators: a randomized controlled trial. *JAMA*. 2005;293:2884–2891.
 39. Leaf A, Albert CM, Josephson M, et al. Prevention of fatal arrhythmias in high-risk subjects by fish oil n-3 fatty acid intake. *Circulation*. 2005;112:2762–2768.
 40. Brouwer IA, Zock PL, Camm AJ, et al. Effect of fish oil on ventricular tachyarrhythmia and death in patients with implantable cardioverter defibrillators: the Study on Omega-3 Fatty Acids and Ventricular Arrhythmia (SOFA) randomized trial. *JAMA*. 2006;295:2613–2619.
 41. Jacobson TA. Secondary prevention of coronary artery disease with omega-3 fatty acids. *Am J Cardiol*. 2006;98:61i–70i.
 42. Tavazzi L, Tognoni G, Franzosi MG, et al. Rationale and design of the GISSI heart failure trial: a large trial to assess the effects of n-3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure. *Eur J Heart Fail*. 2004;6:635–641.
 43. Mozaffarian D, Psaty BM, Rimm EB, et al. Fish intake and risk of incident atrial fibrillation. *Circulation*. 2004;110:368–373.
 44. Calò L, Bianconi L, Colivicchi F, et al. N-3 fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery: a randomized, controlled trial. *J Am Coll Cardiol*. 2005;45:1723–1728.
 45. Crystal E, Garfinkle MS, Connolly SS, Ginger TT, Sleik K, Yusuf SS. Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery. *Cochrane Database Syst Rev*. 2004;(4):CD003611.
 46. Harris WS, Pottala JV, Sands SA, Jones PG. Comparison of the effects of fish and fish-oil capsules on the n-3 fatty acid content of blood cells and plasma phospholipids. *Am J Clin Nutr*. 2007;86:1621–1625.
 47. Block RC, Harris WS, Reid KJ, Sands SA, Spertus JA. EPA and DHA in blood cell membranes from acute coronary syndrome patients and controls. *Atherosclerosis*. 2008;197:821–828. Epub 2007 Sep 17.
 48. Harris WS. Omega-3 fatty acids and cardiovascular disease: a case for omega-3 index as a new risk factor. *Pharmacol Res*. 2007;55:217–223.
 49. Albert CM, Campos H, Stampfer MJ, et al. Blood levels of long-chain n-3 fatty acids and the risk of sudden death. *N Engl J Med*. 2002;346:1113–1118.
 50. O'Keefe JH Jr, Abuissa H, Sastre A, Steinhaus DM, Harris WS. Effects of omega-3 fatty acids on resting heart rate, heart rate recovery after exercise, and heart rate variability in men with healed myocardial infarctions and depressed ejection fractions. *Am J Cardiol*. 2006;97:1127–1130.
 51. Curtis BM, O'Keefe JH Jr. Autonomic tone as a cardiovascular risk factor: the dangers of chronic fight or flight. *Mayo Clin Proc*. 2002;77:45–54.
 52. Ventura HO, Lavie CJ, Messerli FH, et al. Cardiovascular adaptation to cyclosporine-induced hypertension. *J Hum Hypertens*. 1994;8:233–237.
 53. Ventura HO, Milani RV, Lavie CJ, et al. Cyclosporine-induced hypertension. Efficacy of omega-3 fatty acids in patients after cardiac transplantation. *Circulation*. 1993;88:II281–II285.
 54. Abuissa H, O'Keefe JH Jr, Harris W, Lavie CJ. Autonomic function, omega-3, and cardiovascular risk. *Chest*. 2005;127:1088–1091.
 55. Lavie CJ, Milani RV, Squires RW, Boykin C. Exercise and the heart. Good, benign, or evil? *Postgrad Med*. 1992;91:130–134, 143–150.
 56. Harris WS, Gonzales M, Laney N, Sastre A, Borkon AM. Effects of omega-3 fatty acids on heart rate in cardiac transplant recipients. *Am J Cardiol*. 2006;98:1393–1395.
 57. Mehra MR, Lavie CJ, Ventura HO, Milani RV. Fish oils produce anti-inflammatory effects and improve body weight in severe heart failure. *J Heart Lung Transplant*. 2006;25:834–838.
 58. Endres S, Ghorbani R, Kelley VE, et al. The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells. *N Engl J Med*. 1989;320:265–271.
 59. Belluzzi A, Brignola C, Campieri M, Pera A, Boschi S, Miglioli M. Effect of an enteric-coated fish-oil preparation on relapses in Crohn's disease. *N Engl J Med*. 1996;334:1557–1560.
 60. Stenson WF, Cort D, Rodgers J, et al. Dietary supplementation with fish oil in ulcerative colitis. *Ann Intern Med*. 1992;116:609–614.
 61. Harris WS. Expert opinion: omega-3 fatty acids and bleeding: cause for concern? *Am J Cardiol*. 2007;99:44C–46C.
 62. Goodnight SH Jr, Harris WS, Connor WE. The effects of dietary omega 3 fatty acids on platelet composition and function in man: a prospective, controlled study. *Blood*. 1981;58:880–885.
 63. Alaswad K, Pogson GW, Harris WS. Effect of phenytoin, niacin, gemfibrozil, and omega-3 fatty acids on high density lipoproteins in patients with hypoalphalipoproteinemia. *Prev Cardiol*. 1999;2:141–150.
 64. Backgrounder for the 2004 FDA/EPA Consumer Advisory: What you need to know about mercury in fish and shellfish. U.S. Food and Drug Administration. Available at: <http://fda.gov/oc/opacom/hottopics/mercury/backgrounder.html>. 2004. Accessed November 5, 2007.
 65. Foran SE, Flood JG, Lewandrowski KB. Measurement of mercury levels in concentrated over-the-counter fish oil preparations: is fish oil healthier than fish? *Arch Pathol Lab Med*. 2003;127:1603–1605.
 66. Foran JA, Hites RA, Carpenter DO, Hamilton MC, Mathews-Amos A, Schwager SJ. A survey of metals in tissues of farmed Atlantic and wild Pacific salmon. *Environ Toxicol Chem*. 2004;23:2108–2110.
 67. Harris WS. n-3 fatty acids and serum lipoproteins: human studies. *Am J Clin Nutr*. 1997;65(5 suppl):1645S–1654S.
 68. Harris WS, Ginsberg HN, Arunakul N, et al. Safety and efficacy of Omacor in severe hypertriglyceridemia. *J Cardiovasc Risk*. 1997;4:385–391.
 69. Harris WS. International recommendations for consumption of long-chain omega-3 fatty acids. *J Cardiovasc Med. (Hagerstown)*. 2007;8(suppl 1):S50–S52.
 70. Kris-Etherton P, Daniels SR, Eckel RH, et al. Summary of the scientific conference on dietary fatty acids and cardiovascular health: conference summary from the nutrition committee of the American Heart Association. *Circulation*. 2001;103:1034–1039.
 71. Kris-Etherton PM, Harris WS, Appel LJ. American Heart Association. Nutrition Committee. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease [published correction appears in *Circulation*. 2003;107:512]. *Circulation*. 2002;106:2747–2757.
 72. Agricultural Research Service Nutrient Data Laboratory, U.S. Department of Agriculture. Available at: <http://www.nal.usda.gov/fnic/foodcomp/search/>. Accessed November 1, 2007.
 73. Reed SA. More on fish oil [letter]. *N Engl J Med*. 1987;316:625.

74. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults, Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). *JAMA*. 2001;285:2486–2497.
75. World Health Organization, Diet, Nutrition, and the Prevention of Chronic Diseases: Report of a Joint WHO/FAO Expert Consultation. Technical report No. 916. Geneva: World Health Organization. 2003.
76. Priori SG, Aliot E, Blomstrom-Lundqvist C, et al. Update of the guidelines on sudden cardiac death of the European Society of Cardiology. *Eur Heart J*. 2003;24:13–15.
77. Van de Werf F, Ardissino D, Betriu A, et al. Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. *Eur Heart J*. 2003;24:28–66.
78. De Backer G, Ambrosioni E, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. *Eur Heart J*. 2003;24:1601–1610.
79. UK Scientific Advisory Committee on Nutrition, Advice on Fish Consumption Benefits and Risks. London, United Kingdom: The Stationery Office. 2004.
80. Franz MJ, Bantle JP, Beebe CA, et al. Nutrition principles and recommendations in diabetes. *Diabetes Care*. 2004;27(suppl 1): S36–S46.